Medicines Company The Newswire

Medicines Company The Newswire

Comprehensive Real-Time News Feed for Medicines Company The.

Results 1 - 20 of 491 in Medicines Company The

  1. Slate Path Capital LP Position in Medicines Co (MDCO) Has Lifted as...Read the original story

    Yesterday | Hill Country Times

    Slate Path Capital LP Position in Medicines Co Has Lifted as Market Value Declined; Main Street Research Decreased Stake in Facebook as Share Price Rose Main Street Research Llc decreased its stake in Facebook Inc by 1.57% based on its latest 2017Q3 regulatory filing with the SEC. Main Street Research Llc sold 1,982 shares as the company's stock rose 10.88% with the market.

    Comment?

  2. Head-To-Head Contrast: The MedicinesRead the original story w/Photo

    Yesterday | AmericanBankingNews.com

    The Medicines and Hospira are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability. Hospira has lower revenue, but higher earnings than The Medicines.

    Comment?

  3. Eastern Bank Decreased Its Duke Energy (DUK) Holding by $5.85...Read the original story

    Thursday Jan 18 | Hill Country Times

    Eastern Bank Decreased Its Duke Energy Holding by $5.85 Million; Shares Rose; Macquarie Group LTD Upped Its Medicines Co Holding by $3.88 Million; Stock Value Declined Eastern Bank decreased its stake in Duke Energy by 62.03% based on its latest 2017Q3 regulatory filing with the SEC. Eastern Bank sold 70,437 shares as the company's stock rose 6.39% with the market.

    Comment?

  4. The Medicines (MDCO) Given a $50.00 Price Target at OppenheimerRead the original story w/Photo

    Thursday Jan 18 | Daily Political

    Several other research firms have also recently weighed in on MDCO. Zacks Investment Research cut shares of The Medicines from a hold rating to a strong sell rating in a report on Tuesday, October 10th.

    Comment?

  5. Analyzing HospiraRead the original story w/Photo

    Wednesday Jan 17 | The Breeze

    Hospira and The Medicines are both mid-cap generic pharmaceuticals companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations. Hospira has higher earnings, but lower revenue than The Medicines.

    Comment?

  6. Head to Head Survey: The MedicinesRead the original story w/Photo

    Tuesday Jan 16 | Daily Political

    The Medicines and Hospira are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability and analyst recommendations. Hospira has lower revenue, but higher earnings than The Medicines.

    Comment?

  7. Somewhat Positive Media Coverage Somewhat Unlikely to Impact The Medicines (MDCO) Share PriceRead the original story w/Photo

    Monday Jan 15 | IntersportsWire

    Media stories about The Medicines have been trending somewhat positive this week, Accern Sentiment reports. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources.

    Comment?

  8. TiGenix announces publication in Gastroenterology of 52-week results...Read the original story

    Sunday Jan 14 | Customer Interaction Solutions

    January 15, 2018, 07:00 CET - TiGenix NV , an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop novel therapies for serious medical conditions, announces today that the 52-week results of the Phase III ADMIRE-CD trial investigating Cx601 in the treatment of complex perianal fistulas in Crohn's disease have been published in Gastroenterology[1] . This publication in one of the leading scientific publications in the Gastroenterology field provides further validation of the ADMIRE-CD trial results and highlights that Cx601 maintained long-term remission of treatment refractory complex perianal fistulas in patients with Crohn's disease.

    Comment?

  9. As Wal Mart Stores (WMT) Stock Rose, Dorsey & Whitney Trust Company...Read the original story

    Sunday Jan 14 | Hill Country Times

    As Wal Mart Stores Stock Rose, Dorsey & Whitney Trust Company Has Decreased Its Position; Slate Path Capital LP Boosted Medicines Co Stake by $20.91 Million David Greenspan increased its stake in Medicines Co by 103.67% based on its latest 2017Q3 regulatory filing with the SEC. Slate Path Capital Lp bought 565,000 shares as the company's stock declined 20.30% while stock markets rallied.

    Comment?

  10. Artemis Investment Management Llp Lowered Stake in Newfield Expl Co...Read the original story

    Sunday Jan 14 | Hill Country Times

    Artemis Investment Management Llp Lowered Stake in Newfield Expl Co by $354,409 as Valuation Declined; Three Bays Capital LP Trimmed Quintiles Ims Holdings Stake by $14.58 Million; Share Price Rose Three Bays Capital Lp decreased its stake in Quintiles Ims Holdings Inc by 14.39% based on its latest 2017Q3 regulatory filing with the SEC. Three Bays Capital Lp sold 153,500 shares as the company's stock rose 8.21% with the market.

    Comment?

  11. Hospira (HSP) and The Medicines (MDCO) Critical ComparisonRead the original story w/Photo

    Friday Jan 12 | IntersportsWire

    Hospira and The Medicines are both mid-cap generic pharmaceuticals companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, valuation, risk and analyst recommendations. Hospira has higher earnings, but lower revenue than The Medicines.

    Comment?

  12. Reviewing HospiraRead the original story w/Photo

    Thursday Jan 11 | AmericanBankingNews.com

    Hospira and The Medicines are both generic pharmaceuticals companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, earnings, dividends, profitability, valuation and risk. This is a breakdown of recent recommendations and price targets for Hospira and The Medicines, as reported by MarketBeat.com.

    Comment?

  13. Hospira (HSP) & The Medicines (MDCO) Critical ReviewRead the original story w/Photo

    Wednesday Jan 10 | AmericanBankingNews.com

    Hospira and The Medicines are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations. Hospira has higher earnings, but lower revenue than The Medicines.

    Comment?

  14. The Medicines Company (MDCO) Expected to Announce Quarterly Sales of $20.38 MillionRead the original story w/Photo

    Monday Jan 8 | AmericanBankingNews.com

    Analysts predict that The Medicines Company will post $20.38 million in sales for the current quarter, according to Zacks Investment Research . Four analysts have made estimates for The Medicines' earnings.

    Comment?

  15. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story w/Photo

    Monday Jan 8 | Business Wire

    Customers who s... )--Baker Hill, a leading provider of technology solutions for commercial loan origination, risk management, relationship management and smart data analytics, has expande... )--On Wednesday, February 7, 2018, Xcel Energy will host a conference call to review fourth quarter 2017 financial results.

    Comment?

  16. The Medicines Company Announces Closing of Divestiture of Infectious...Read the original story

    Monday Jan 8 | Customer Interaction Solutions

    The Medicines Company today announced the closing of the sale of its infectious disease business unit to Melinta Therapeutics, Inc. for consideration consisting of $215 million of guaranteed cash, approximately 3.3 million shares of Melinta common stock, tiered royalty payments of 5% to 25% on worldwide net sales of Vabomere, Orbactiv and Minocin IV, and the assumption by Melinta of all royalty, milestone and other payment obligations relating to those products. "The sale of our infectious disease business to Melinta Therapeutics successfully completes a crucial step in the Company's strategic evolution, which we initially outlined in late 2015," said Clive Meanwell, M.D., Ph.D., Chief Executive Officer of The Medicines Company.

    Comment?

  17. Alnylam Announces 2018 Corporate GoalsRead the original story

    Sunday Jan 7 | Customer Interaction Solutions

    Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today announced its corporate goals for 2018. The goals focus on clinical and regulatory progress against its five mid- to late-stage programs, including patisiran, which is advancing toward potential global regulatory approvals and commercialization, paving the way for the Company to achieve its Alnylam 2020 goals.

    Comment?

  18. Zacks: Brokerages Anticipate The Medicines Company (MDCO) to Announce -$1.48 EPSRead the original story w/Photo

    Saturday Jan 6 | AmericanBankingNews.com

    Wall Street analysts expect The Medicines Company to announce earnings of per share for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for The Medicines' earnings, with the highest EPS estimate coming in at and the lowest estimate coming in at .

    Comment?

  19. Three Bays Capital LP Holding in Zayo Group Hldgs (ZAYO) Has...Read the original story

    Saturday Jan 6 | Hill Country Times

    Three Bays Capital LP Holding in Zayo Group Hldgs Has Decreased as Stock Price Rose; As Abbott Laboratories Share Value Declined, Private Trust Co Has Lowered by $462,531 Its Stake Private Trust Co decreased its stake in Abbott Laboratories by 13.45% based on its latest 2017Q3 regulatory filing with the SEC. Private Trust Co sold 8,727 shares as the company's stock declined 3.42% while stock markets rallied.

    Comment?

  20. View Press ReleaseRead the original story w/Photo

    Friday Jan 5 | Business Wire

    The total payment to be received by the Fund is listed below. When the Fund calculates its net asset value per share on Monday, January 8, 2018, it is estimated that the Fund's NAV will be impacted by the amount stated below based on shares outstanding as of January 4, 2018.

    Comment?